Izrael - hebrajski - Ministry of Health

a.l. medi-market ltd. - selamectin - selamectin 120 mg / 1 ml

Izrael - hebrajski - Ministry of Health

a.l. medi-market ltd. - selamectin - selamectin 60 mg / 1 ml

Izrael - hebrajski - Ministry of Health

lidorr elements ltd - imidacloprid; moxidectin - תמיסה - imidacloprid 100 mg/ml; moxidectin 25 mg/ml - for dogs suffering from or at risk from mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalides felis) treatment of biting lice (trichodectes canis) treatment of ear mit infestation (otodectes cynotis) sarcoptic mange (caused by sarcoptes scabiei var. canys) demodicosis ( caused by demodex canis) prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis) treatment of angiostrongylus vasorum adn treatment of infections with gastrointestinal nematodes (l4 larve immature adults and adults of toxocara canis ancylostoma caninum and uncinaria stenocephala adults of toxascaris leonina and trichuris vulpis). the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).

Izrael - hebrajski - Ministry of Health

zoetis israel holding b.v., israel - sarolaner; selamectin - תמיסה - sarolaner 10 mg / 1 ml; selamectin 60 mg / 1 ml

Izrael - hebrajski - Ministry of Health

lidorr elements ltd - imidacloprid; moxidectin - תמיסה - imidacloprid 100 mg/ml; moxidectin 10 mg/ml - cats:for cats suffering from or at risk from mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalides felis) treatment of ear mit infestation (otodectes cynotis) prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis) and treatment of infections with gastrointestinal nematodes (l4 larve immature adults and adults of toxocara cati ancylostoma tubaeforne). the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).ferrets:for ferrets suffering from, or at risk from, mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalidas felis ) and the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis)

Izrael - hebrajski - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 20 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to thes

Izrael - hebrajski - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures.- reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios.homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these

Izrael - hebrajski - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 80 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures.reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measure

Izrael - hebrajski - Ministry of Health

teva israel ltd - simvastatin - טבליה - simvastatin 40 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: reduce the risk of total mortality by reducing coronary death ;reduce the risk of non-fatal myocardial infarction ;reduce the risk for undergoing myocardial revascularization procedures. reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these meas

Izrael - hebrajski - Ministry of Health

abic ltd. - ofloxacin - טבליה - ofloxacin 200 mg - ofloxacin - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).